Soligenix, Inc. (SNGX)
Nasdaq · Healthcare · Biotechnology
$0.359−1.27%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $7.8M
- 52-week range
- $0.28 – $1.97
- 52-week change
- −72.99%
- EPS (trailing)
- −$0.79
Fiscal year to Dec 2025
- Net income
- −$11.1M
- Diluted EPS
- −$2.14
- Free cash flow
- −$10.3M
From the company’s annual report on SEC EDGAR.
About Soligenix, Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis.
Headquarters: Princeton, United States · 13 employees · soligenix.com